Clinical Trials List
2025-09-24 - 2028-11-30
Phase I
Recruiting3
ICD-10C45.9
Mesothelioma, unspecified
ICD-10C79.9
Secondary malignant neoplasm of unspecified site
ICD-10C7A.00
Malignant carcinoid tumor of unspecified site
ICD-10C7A.094
Malignant carcinoid tumor of the foregut NOS
ICD-10C7A.095
Malignant carcinoid tumor of the midgut NOS
ICD-10C7A.096
Malignant carcinoid tumor of the hindgut NOS
ICD-10C7A.1
Malignant poorly differentiated neuroendocrine tumors
ICD-10C7A.8
Other malignant neuroendocrine tumors
ICD-10C7B.00
Secondary carcinoid tumors, unspecified site
ICD-10C80.1
Malignant (primary) neoplasm, unspecified
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9199.1
Malignant neoplasm of unspecified site (primary) (secondary)
A First-In-Human, Phase 1, Open-Label, Multicenter Study of ZW251, a Novel Glypican-3 Targeting Antibody-Drug Conjugate, in Participants with Advanced Solid Tumors, Including Hepatocellular Carcinoma
-
Sponsor
PPD DEVELOPMENT (HK) LIMITED TAIWAN BRANCH
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/02/01
Investigators and Locations
Co-Principal Investigator
- San-Chi Chen Division of Hematology & Oncology
- I-Cheng Lee Digestive System Department
- 吳啟榮 Digestive System Department
- Chien-An Liu Division of Radiology
- 齊振達 Digestive System Department
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- TSUNG-HAO LIU Division of Hematology & Oncology
- 莊建淮 Division of Hematology & Oncology
- Ying-Chun Shen Division of Hematology & Oncology
- 呂理駿 Division of Hematology & Oncology
- Chih-Hung Hsu Division of Hematology & Oncology
- YU-YUN SHAO
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 賴盈潔 Division of Radiology
- Chao-Wei Hsu Digestive System Department
- Ming-Mo Hou Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Incidence of dose-limiting toxicities (DLTs; Part 1)
Incidence of AEs (Parts 1 and 2)
Incidence of clinical laboratory abnormalities (Parts 1 and 2)
Confirmed objective response rate (Part 2)
Inclution Criteria
• Pathologically or cytologically confirmed diagnosis of HCC with evidence of locally advanced (unresectable, and ineligible for transplant) and/or metastatic disease. Noninvasive methods may be used to confirm diagnosis
• Measurable disease per RECIST v1.1
• Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1
• Liver function status of Child-Pugh Class A
• Adequate organ function
Exclusion Criteria
• Known additional malignancy that is progressing or that has required active treatment within the last year
• History of hepatic encephalopathy within the past 6 months or requirement for medications to control encephalopathy
• Portal vein thrombosis within 3 months prior to Cycle 1 Day 1 that require coagulation therapy or is not stable
• Known gastrointestinal bleeding within 3 months
• Acute or chronic uncontrolled renal disease, pancreatitis, or non-malignant liver disease
The Estimated Number of Participants
-
Taiwan
16 participants
-
Global
100 participants
